Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Indolent Lymphoma Overview 10 Therapeutics Development 11 Pipeline Products for Indolent Lymphoma - Overview 11 Indolent Lymphoma - Therapeutics under Development by Companies 12 Indolent Lymphoma - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Indolent Lymphoma - Products under Development by Companies 16 Indolent Lymphoma - Companies Involved in Therapeutics Development 18 AbbVie Inc. 18 Affimed Therapeutics AG 19 Altor BioScience Corporation 20 Astellas Pharma Inc. 21 AstraZeneca Plc 22 Bayer AG 23 Biothera, Inc. 24 Boehringer Ingelheim GmbH 25 Bristol-Myers Squibb Company 26 Celgene Corporation 27 F. Hoffmann-La Roche Ltd. 28 Gilead Sciences, Inc. 29 Incyte Corporation 30 Infinity Pharmaceuticals, Inc. 31 Juno Therapeutics Inc. 32 Kite Pharma, Inc. 33 MedImmune, LLC 34 Merck & Co., Inc. 35 Merck KGaA 36 Millennium Pharmaceuticals, Inc. 37 MorphoSys AG 38 Trillium Therapeutics Inc. 39 Indolent Lymphoma - Therapeutics Assessment 40 Assessment by Monotherapy Products 40 Assessment by Combination Products 41 Assessment by Target 42 Assessment by Mechanism of Action 45 Assessment by Route of Administration 47 Assessment by Molecule Type 49 Drug Profiles 51 acalisib - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 AFM-11 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 ALT-803 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 AZD-6738 - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 bendamustine hydrochloride - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 BI-836826 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 BMS-986016 - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 BTH-1677 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 CC-122 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 copanlisib hydrochloride - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 DI-B4 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 duvelisib - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 entospletinib - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 ibrutinib - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 idelalisib - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 INCB-40093 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 INCB-50465 - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 inebilizumab - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 inebilizumab + MEDI-0680 - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 inebilizumab + rituximab - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 itacitinib adipate - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 JCAR-014 - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 JCAR-015 - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 KTEC-19 - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 lenalidomide - Drug Profile 105 Product Description 105 Mechanism of Action 105 R&D Progress 105 MOR-208 - Drug Profile 110 Product Description 110 Mechanism of Action 110 R&D Progress 110 obinutuzumab - Drug Profile 112 Product Description 112 Mechanism of Action 112 R&D Progress 112 TAK-659 - Drug Profile 115 Product Description 115 Mechanism of Action 115 R&D Progress 115 TTI-621 - Drug Profile 116 Product Description 116 Mechanism of Action 116 R&D Progress 116 venetoclax - Drug Profile 118 Product Description 118 Mechanism of Action 118 R&D Progress 118 vorinostat - Drug Profile 122 Product Description 122 Mechanism of Action 122 R&D Progress 122 Indolent Lymphoma - Recent Pipeline Updates 126 Indolent Lymphoma - Dormant Projects 204 Indolent Lymphoma - Discontinued Products 205 Indolent Lymphoma - Product Development Milestones 206 Featured News & Press Releases 206 Nov 30, 2015: New Data from Bayer’s Portfolio in Oncology to be Presented at ASH 2015 206 Dec 01, 2014: Bayer To Present Phase II Clinical Trials Data On Copanlisib At ASH 56th Annual Meeting 206 Apr 07, 2014: Research Expands Understanding of Biomarker for Biothera Cancer Immunotherapy Imprime PGG 206 Jan 22, 2014: New drug shows promise in treating indolent non-Hodgkin lymphomas 207 Dec 10, 2013: Studies Evaluating REVLIMID (Lenalidomide) in Lymphoma Presented at ASH 208 Dec 08, 2013: Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin’s Lymphoma 210 Feb 20, 2013: Phase 3 data published in The Lancet show bendamustine plus rituximab doubles progression-free survival in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma compared with CHOP-R 211 Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting 212 Dec 03, 2012: Record number of bendamustine abstracts accepted for presentation at the Annual Meeting of the American Society of Hematology (ASH) 213 Dec 07, 2010: Celgene Presents Clinical Data From Two Phase II Studies Evaluating REVLIMID Plus Rituximab In Indolent Non-Hodgkin’s Lymphomas At ASH 215 Appendix 217 Methodology 217 Coverage 217 Secondary Research 217 Primary Research 217 Expert Panel Validation 217 Contact Us 217 Disclaimer 218

List of Tables Number of Products under Development for Indolent Lymphoma, H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Products under Development by Companies, H1 2016 16 Products under Development by Companies, H1 2016 (Contd..1) 17 Indolent Lymphoma - Pipeline by AbbVie Inc., H1 2016 18 Indolent Lymphoma - Pipeline by Affimed Therapeutics AG, H1 2016 19 Indolent Lymphoma - Pipeline by Altor BioScience Corporation, H1 2016 20 Indolent Lymphoma - Pipeline by Astellas Pharma Inc., H1 2016 21 Indolent Lymphoma - Pipeline by AstraZeneca Plc, H1 2016 22 Indolent Lymphoma - Pipeline by Bayer AG, H1 2016 23 Indolent Lymphoma - Pipeline by Biothera, Inc., H1 2016 24 Indolent Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 25 Indolent Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016 26 Indolent Lymphoma - Pipeline by Celgene Corporation, H1 2016 27 Indolent Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 28 Indolent Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016 29 Indolent Lymphoma - Pipeline by Incyte Corporation, H1 2016 30 Indolent Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016 31 Indolent Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2016 32 Indolent Lymphoma - Pipeline by Kite Pharma, Inc., H1 2016 33 Indolent Lymphoma - Pipeline by MedImmune, LLC, H1 2016 34 Indolent Lymphoma - Pipeline by Merck & Co., Inc., H1 2016 35 Indolent Lymphoma - Pipeline by Merck KGaA, H1 2016 36 Indolent Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 37 Indolent Lymphoma - Pipeline by MorphoSys AG, H1 2016 38 Indolent Lymphoma - Pipeline by Trillium Therapeutics Inc., H1 2016 39 Assessment by Monotherapy Products, H1 2016 40 Assessment by Combination Products, H1 2016 41 Number of Products by Stage and Target, H1 2016 43 Number of Products by Stage and Mechanism of Action, H1 2016 46 Number of Products by Stage and Route of Administration, H1 2016 48 Number of Products by Stage and Molecule Type, H1 2016 50 Indolent Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016 126 Indolent Lymphoma - Dormant Projects, H1 2016 204 Indolent Lymphoma - Discontinued Products, H1 2016 205 List of Figures Number of Products under Development for Indolent Lymphoma, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Comparative Analysis by Late Stage Development, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Assessment by Monotherapy Products, H1 2016 40 Number of Products by Top 10 Targets, H1 2016 42 Number of Products by Stage and Top 10 Targets, H1 2016 42 Number of Products by Top 10 Mechanism of Actions, H1 2016 45 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 45 Number of Products by Routes of Administration, H1 2016 47 Number of Products by Stage and Routes of Administration, H1 2016 47 Number of Products by Molecule Types, H1 2016 49 Number of Products by Stage and Molecule Types, H1 2016 49

AbbVie Inc. Affimed Therapeutics AG Altor BioScience Corporation Astellas Pharma Inc. AstraZeneca Plc Bayer AG Biothera, Inc. Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Celgene Corporation F. Hoffmann-La Roche Ltd. Gilead Sciences, Inc. Incyte Corporation Infinity Pharmaceuticals, Inc. Juno Therapeutics Inc. Kite Pharma, Inc. MedImmune, LLC Merck & Co., Inc. Merck KGaA Millennium Pharmaceuticals, Inc. MorphoSys AG Trillium Therapeutics Inc.